MX2023006511A - Un anticuerpo monoclonal inhibidor del factor xiia. - Google Patents

Un anticuerpo monoclonal inhibidor del factor xiia.

Info

Publication number
MX2023006511A
MX2023006511A MX2023006511A MX2023006511A MX2023006511A MX 2023006511 A MX2023006511 A MX 2023006511A MX 2023006511 A MX2023006511 A MX 2023006511A MX 2023006511 A MX2023006511 A MX 2023006511A MX 2023006511 A MX2023006511 A MX 2023006511A
Authority
MX
Mexico
Prior art keywords
monoclonal antibody
factor xiia
antibody inhibitor
factor
diseases associated
Prior art date
Application number
MX2023006511A
Other languages
English (en)
Inventor
Jon A Kenniston
Burt Adelman
Stephen R Comeau
Andrew Nixon
Shauna Mason
Daniel J Sexton
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of MX2023006511A publication Critical patent/MX2023006511A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Acá se divulgan anticuerpos anti-Factor XIIa y método para usar los mismos para el tratamiento de enfermedades asociadas con Factor XII, incluyendo enfermedades asociadas con activación de sistema de contacto, señalización de precalicreína de plasma (por ejemplo, angioedema hereditario), y enfermedades oculares.
MX2023006511A 2015-07-21 2018-01-17 Un anticuerpo monoclonal inhibidor del factor xiia. MX2023006511A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562194957P 2015-07-21 2015-07-21
US201562273657P 2015-12-31 2015-12-31
US201662316310P 2016-03-31 2016-03-31

Publications (1)

Publication Number Publication Date
MX2023006511A true MX2023006511A (es) 2023-06-21

Family

ID=56555827

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018000714A MX2018000714A (es) 2015-07-21 2016-07-21 Un inhibidor de anticuerpo monoclonal de factor xiia.
MX2023006511A MX2023006511A (es) 2015-07-21 2018-01-17 Un anticuerpo monoclonal inhibidor del factor xiia.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2018000714A MX2018000714A (es) 2015-07-21 2016-07-21 Un inhibidor de anticuerpo monoclonal de factor xiia.

Country Status (14)

Country Link
US (2) US10913802B2 (es)
EP (2) EP3325516B1 (es)
JP (3) JP7068160B2 (es)
KR (1) KR20180096567A (es)
CN (2) CN108137705B (es)
AU (2) AU2016297018B9 (es)
BR (1) BR112018001202A2 (es)
CA (1) CA2993026A1 (es)
CO (1) CO2018001599A2 (es)
EA (1) EA201890340A1 (es)
HK (1) HK1255423A1 (es)
IL (1) IL257047B1 (es)
MX (2) MX2018000714A (es)
WO (1) WO2017015431A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015373910B2 (en) 2015-01-02 2021-11-18 Takeda Pharmaceutical Company Limited Bispecific antibodies against plasma kallikrein and factor XII
IL257047B1 (en) 2015-07-21 2024-07-01 Dyax Corp A monoclonal antibody that inhibits factor XIIA
CN109260462B (zh) * 2018-08-24 2021-05-11 上海交通大学医学院附属瑞金医院 一种凝血酶原突变体蛋白及其编码核酸的应用
KR20220109451A (ko) * 2019-12-03 2022-08-04 씨에스엘 이노베이션 피티와이 엘티디 유전성 혈관부종의 치료 또는 예방을 위한 항-인자 xii 항체의 용도
BR112022026533A2 (pt) * 2020-07-02 2023-01-17 Beijing Tuo Jie Biopharmaceutical Co Ltd Anticorpo anti-fxi/fxia, fragmento de ligação do mesmo, e antígenos e uso farmacêutico do mesmo
IL298989A (en) * 2020-07-03 2023-02-01 CSL Innovation Pty Ltd High concentration promotion of factor XII antigen binding proteins
US20230390418A1 (en) * 2020-10-29 2023-12-07 Regenxbio Inc. Vectorized factor xii antibodies and administration thereof
MX2023011919A (es) * 2021-04-07 2023-10-19 Mythic Therapeutics Inc Construcciones de proteinas de union a antigenos y anticuerpos y usos de estos.

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
US4963657A (en) 1988-06-09 1990-10-16 Temple University Of The Commonwealth System Of Higher Education Monoclonal antibodies to the light chain region of human factor XII and methods of preparing and using the same
JP2752788B2 (ja) 1989-01-23 1998-05-18 カイロン コーポレイション 感染および過剰増殖障害の為の組換え療法
GB8901859D0 (en) 1989-01-27 1989-03-15 Shield Diagnostics Limited Diagnostic test
US5500349A (en) 1989-01-27 1996-03-19 Coagen Limited Blood-coagulation factor XIIA β monoclonal antibody and immunoassay
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
ATE240401T1 (de) 1989-03-21 2003-05-15 Vical Inc Expression von exogenen polynukleotidsequenzen in wirbeltieren
WO1991002805A2 (en) 1989-08-18 1991-03-07 Viagene, Inc. Recombinant retroviruses delivering vector constructs to target cells
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
ZA911974B (en) 1990-03-21 1994-08-22 Res Dev Foundation Heterovesicular liposomes
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
WO1991017258A1 (en) 1990-05-10 1991-11-14 Cetus Corporation Inhibitors of factor xii activation and applications thereof
EP0648271B1 (en) 1991-08-20 2003-04-16 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Adenovirus mediated transfer of genes to the gastrointestinal tract
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
GB9125623D0 (en) 1991-12-02 1992-01-29 Dynal As Cell modification
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
JPH07507689A (ja) 1992-06-08 1995-08-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 特定組織のターゲティング方法及び組成物
JPH09507741A (ja) 1992-06-10 1997-08-12 アメリカ合衆国 ヒト血清による不活性化に耐性のあるベクター粒子
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
WO1994012649A2 (en) 1992-12-03 1994-06-09 Genzyme Corporation Gene therapy for cystic fibrosis
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
DE69431750T2 (de) 1993-04-22 2003-04-03 Skyepharma Inc., San Diego Multivesikuläre liposomen mit verkapseltem cyclodextrin und pharmakologisch wirksamen verbindungen sowie verfahren zu deren verwendung
ATE304604T1 (de) 1993-06-24 2005-09-15 Frank L Graham Adenovirus vektoren für gentherapie
EP0982405B1 (en) 1993-09-15 2009-08-26 Novartis Vaccines and Diagnostics, Inc. Recombinant alphavirus vectors
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
SK283703B6 (sk) 1993-10-25 2003-12-02 Canji, Inc. Rekombinantný adenovírusový vektor a jeho použitie
RU2160093C2 (ru) 1993-11-16 2000-12-10 Скайефарма Инк. Везикулы с регулируемым высвобождением активных ингредиентов
ES2297831T3 (es) 1994-05-09 2008-05-01 Oxford Biomedica (Uk) Limited Vectores retroviricos que presentan una tasa de recombinacion reducida.
WO1996017072A2 (en) 1994-11-30 1996-06-06 Chiron Viagene, Inc. Recombinant alphavirus vectors
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
GB9609262D0 (en) 1996-05-02 1996-07-03 Isis Innovation Peptide library and method
ATE424463T1 (de) 1996-05-06 2009-03-15 Oxford Biomedica Ltd Rekombinationsunfähige retrovirale vektoren
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
EP1158997A2 (en) 1999-03-09 2001-12-05 University Of Southern California Method of promoting myocyte proliferation and myocardial tissue repair
KR101277097B1 (ko) 2004-12-23 2013-06-20 체에스엘 베링 게엠베하 혈전 형성 및/또는 안정화의 예방
GB0500487D0 (en) * 2005-01-11 2005-02-16 Axis Shield Diagnostics Ltd Forms of factor XIIa
US7932021B2 (en) 2005-07-28 2011-04-26 American Diagnostica, Inc. Lupus anticoagulant testing
GB0607515D0 (en) 2006-04-13 2006-05-24 Axis Shield Diagnostics Ltd Anti-factor xlla therapy
TWI538916B (zh) * 2008-04-11 2016-06-21 介控生化科技公司 經修飾的因子vii多肽和其用途
TWI496582B (zh) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
SI2521568T1 (sl) 2010-01-06 2019-01-31 Dyax Corp. Proteini, ki vežejo plazemski kalikrein
IL269565B2 (en) 2011-01-06 2024-06-01 Dyax Corp KALLIKREIN PLASMA BINDING PROTEINS
CN103687878B (zh) 2011-07-22 2018-01-09 德国杰特贝林生物制品有限公司 抑制性的抗因子xii/xiia单克隆抗体及其用途
JP5653860B2 (ja) 2011-07-28 2015-01-14 富士フイルム株式会社 管壁の硬度測定方法および装置
EP2765192A4 (en) 2011-10-05 2015-04-15 Chugai Pharmaceutical Co Ltd ANTIGEN BINDING MOLECULE FOR PROMOTING THE PLASMA CLAIR OF AN ANTIGEN COMPRISING A SACCHARIDIC CHAIN TYPE RECEPTOR BINDING DOMAIN
SI2794905T1 (sl) 2011-12-20 2020-08-31 Medimmune, Llc Modificirani polipeptidi za ogrodja bispecifičnega protitelesa
WO2014019644A1 (en) 2012-07-31 2014-02-06 Baxter International Inc. Selective measurement of active human protease coagulation factors
US9574013B2 (en) * 2012-12-07 2017-02-21 Vanderbilt University Antibodies against factor XII and uses thereof
CN110208533B (zh) 2013-01-20 2023-01-10 武田药品工业株式会社 Pkal-介导的病症的评估、测定和治疗
EP2970502A4 (en) 2013-03-15 2016-11-30 Dyax Corp ANTI-PLASMA KALLIKREIN ANTIBODY
JP2017501968A (ja) 2013-06-28 2017-01-19 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 第ｘｉｉ因子インヒビターおよびｃ１−インヒビターを使用する組合せ療法
DK3024851T3 (en) 2013-07-25 2018-08-06 Cytomx Therapeutics Inc MULTI-SPECIFIC ANTIBODIES, MULTI-SPECIFICALLY ACTIVABLE ANTIBODIES, AND METHODS FOR USING IT
AU2015373910B2 (en) 2015-01-02 2021-11-18 Takeda Pharmaceutical Company Limited Bispecific antibodies against plasma kallikrein and factor XII
IL257047B1 (en) 2015-07-21 2024-07-01 Dyax Corp A monoclonal antibody that inhibits factor XIIA

Also Published As

Publication number Publication date
JP7068160B2 (ja) 2022-05-16
HK1255423A1 (zh) 2019-08-16
BR112018001202A2 (pt) 2018-09-25
CN108137705B (zh) 2022-11-08
IL257047A (en) 2018-03-29
IL257047B1 (en) 2024-07-01
AU2016297018A1 (en) 2018-02-08
EP3325516A1 (en) 2018-05-30
US10913802B2 (en) 2021-02-09
NZ739088A (en) 2024-01-26
EP4011916A1 (en) 2022-06-15
CN108137705A (zh) 2018-06-08
WO2017015431A1 (en) 2017-01-26
CA2993026A1 (en) 2017-01-26
JP7317891B2 (ja) 2023-07-31
MX2018000714A (es) 2019-11-18
US20190002584A1 (en) 2019-01-03
AU2016297018B2 (en) 2022-08-11
EA201890340A1 (ru) 2018-09-28
JP2023145564A (ja) 2023-10-11
JP2018520684A (ja) 2018-08-02
CN116333144A (zh) 2023-06-27
CO2018001599A2 (es) 2018-05-10
EP3325516B1 (en) 2021-12-15
AU2016297018B9 (en) 2022-12-01
JP2021121615A (ja) 2021-08-26
US20210230299A1 (en) 2021-07-29
KR20180096567A (ko) 2018-08-29
AU2022268373A1 (en) 2022-12-15
WO2017015431A8 (en) 2017-03-23

Similar Documents

Publication Publication Date Title
MX2023006511A (es) Un anticuerpo monoclonal inhibidor del factor xiia.
NZ753515A (en) Methods for treatment of cancer comprising tigit-binding agents
NZ738008A (en) Tigit-binding agents and uses thereof
BR112017007170A2 (pt) anticorpos anti-ox40 humanizados e suas utilizações
EP4223874A3 (en) Human anti-il-33 neutralizing monoclonal antibody
MX2019011423A (es) Metodos de tratamiento de enfermedades neurodegenerativas.
BR112017022838A2 (pt) receptores quiméricos de antígeno de antígenos de mieloma kappa e seus usos
BR112017009817A2 (pt) anticorpos anti-il-1beta e métodos de utilização
EA201691470A1 (ru) Белки, связывающие калликреин плазмы, и их применение для лечения наследственного ангионевротического отека
MX2017008541A (es) Anticuerpos biespecificos contra calicreina y factor xii del plasma.
PH12019500145A1 (en) HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-á)
BR112021011684A2 (pt) Terapia combinada com cd70 e venetoclax, um inibidor de bcl-2, para o tratamento da leucemia mieloide aguda
WO2014186622A3 (en) Methods of treatment for guillain-barre syndrome
EA201792161A1 (ru) Ингибиторы калликреинов плазмы и их применение для профилактики приступа наследственного ангионевротического отека
EA201891388A1 (ru) Ингибиторы калликреина плазмы и их применение для лечения обострения наследственного ангионевротического отека
BR112022003956A2 (pt) Anticorpos anti-cd73
MX2020010269A (es) Un anticuerpo anti-il-23p 19 (mirikizumab) para usarse en el tratamiento de la colitis ulcerosa.
EA201991876A1 (ru) Антитела против фактора d и их применения
PH12019500711A1 (en) Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy
MX2019000429A (es) Anticuerpo dirigido contra s100a9 humanizado y usos del mismo.
PH12015501650A1 (en) Human antibody specific to human metapneumovirus, or antigen-binding fragment thereof
EP4218817A3 (en) Methods for treating metabolic diseases by inhibiting myostatin activation
CR20220228A (es) Anticuerpos trem2 y usos de estos
PH12017502126A1 (en) Novel anti-human ngf antibody fab fragment
BR112018007551A2 (pt) método para detectar anticorpos neutralizantes contra insulina humana recombinante em soro humano